The Centers for Disease Control and Prevention (CDC) awarded a multiple-award, indefinite-delivery, indefinite-quantity (IDIQ) contract valued up to $99,015,000 to Bavarian Nordic, Inc. for the procurement of various adult vaccines. The contract period of performance runs from July 1, 2024 to June 30, 2025. The required vaccine types include Hepatitis A, Hepatitis B, Hepatitis A&B combination, Herpes Zoster, Human Papillomavirus (HPV9), E-IPV, Measles/Mumps/Rubella, Meningococcal, Mpox, Pneumococcal, Tetanus/Diphtheria, and Varicella. The solicitation outlines estimated maximum and minimum quantities for each vaccine type, but does not provide an overall contract value or budget range. Bavarian Nordic, a biotechnology company focused on infectious disease vaccines, has previously provided rabies vaccines to the CDC and Department of Agriculture through other contract vehicles such as Federal Supply Schedule contracts and blanket purchase agreements.
The contract is not set-aside and the applicable North American Industry Classification System (NAICS) code is 325412 - Pharmaceutical Preparation Manufacturing. Contractors must be FDA-licensed vaccine manufacturers and proposals were due by April 5, 2024. Vaccines will be ordered through the CDC's Vaccine Tracking System (VTrckS) using a fair opportunity process. The place of performance is the United States. This IDIQ contract provides the CDC with a flexible mechanism to efficiently procure a range of adult vaccines on an as-needed basis to support the agency's public health mission.
Generated 2/4/25, 10:20 AM